The cancer anorexia-cachexia syndrome is one of the most common causes of death among cancer patients and is present in 80% at death. It is a complex example of metabolic chaos effecting protein, carbohydrate, and fat metabolism. Tumors produce both direct and indirect abnormalities, resulting in anorexia and weight loss. The disease burden does not correlate with the degree of cachexia. Although there is no treatment to control or reverse the process, appetite stimulants may promote increased food intake and enhance quality of life.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation.
Front Immunol
December 2024
Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
Background: Cachexia is a leading cause of death among individuals with advanced cancer, yet effective pharmacological treatments are lacking. In this single-center retrospective study, we aimed to investigate the efficacy and safety of tocilizumab for the treatment of cancer cachexia accompanied by systemic hyperinflammation.
Methods: Data were collected from 20 patients treated with tocilizumab and a control group of 20 patients matched for age, sex, and comorbidities.
Treatment of choice for malignant gastric outlet obstruction: More than clearing the road.
World J Gastrointest Endosc
November 2024
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China.
In this editorial, we comment on the in-press article in the concerning the treatment of malignant gastric outlet obstruction (mGOO). The original theory of treatment involves bypassing the obstruction or reenabling the patency of the passage. Conventional surgical gastroenterostomy provides long-term relief of symptoms in selected patients, with substantial morbidity and a considerable rate of delayed gastric emptying.
View Article and Find Full Text PDFGDF15 research from bench to bedside.
Cancer Cell
November 2024
St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address:
Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may be approaching.
View Article and Find Full Text PDFImpact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
J Cachexia Sarcopenia Muscle
December 2024
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Article Synopsis
- Cancer cachexia frequently occurs in advanced non-small cell lung cancer (NSCLC) and its impact on chemotherapy is not fully understood.
- A study involving 887 NSCLC patients identified that 31.7% experienced weight loss indicative of cachexia, with variations in quality of life (QOL) observed across different treatment groups.
- Results showed that quality of life declined more significantly in chemotherapy patients compared to those receiving targeted therapies or immune checkpoint inhibitors, especially within the first week of treatment.
The LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and Patients.
Endocrinology
September 2024
Center for Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Article Synopsis
- The hormone ghrelin plays a protective role in cancer-related anorexia-cachexia syndrome (CACS), with its levels rising to help combat weight loss and anorexia in cancer patients.
- A study found that deleting ghrelin worsened body weight and fat loss in mice with cancer, while deleting LEAP2, a ghrelin antagonist, seemed to lessen the severity of CACS.
- In human patients with CACS, a lower ratio of plasma LEAP2 to total ghrelin was associated with better weight stability, indicating a possible protective mechanism against worsening CACS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!